CY1115631T1 - Νεες πολυμορφικες μορφες του υδροχλωρικου αλατος 3-(1-{3-[5-(1-μεθυλ-πιπεριδιν-4-υλμεθοξυ)-πυριμιδιν-2-υλ]-βενζυλ}-6-οξο-1,6-διυδρο-πυριδαζιν-3-υλ)-βενζονιτριλιου και διαδικασιες για την παρασκευη του - Google Patents

Νεες πολυμορφικες μορφες του υδροχλωρικου αλατος 3-(1-{3-[5-(1-μεθυλ-πιπεριδιν-4-υλμεθοξυ)-πυριμιδιν-2-υλ]-βενζυλ}-6-οξο-1,6-διυδρο-πυριδαζιν-3-υλ)-βενζονιτριλιου και διαδικασιες για την παρασκευη του

Info

Publication number
CY1115631T1
CY1115631T1 CY20141100845T CY141100845T CY1115631T1 CY 1115631 T1 CY1115631 T1 CY 1115631T1 CY 20141100845 T CY20141100845 T CY 20141100845T CY 141100845 T CY141100845 T CY 141100845T CY 1115631 T1 CY1115631 T1 CY 1115631T1
Authority
CY
Cyprus
Prior art keywords
benzyl
ylmethoxy
benzonitrile
pyrimidin
piperidin
Prior art date
Application number
CY20141100845T
Other languages
English (en)
Inventor
Axel Becker
Clemens Kuehn
Christoph Saal
Oliver Schadt
Dieter Dorsch
Heinz-Hermann Bokel
Frank Stieber
Christina Donini
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41572530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115631(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CY1115631T1 publication Critical patent/CY1115631T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με υδροχλωρικά διαλύματα του 3-(1-{3-[5-(1-μεθυλ-πιπεριδιν-4-υλμεθοξυ)-πυριμιδιν-2-υλ]-βενζυλ}-6-οξο-1,6-διυδρο-πυριδαζιν-3-υλ)-βενζονιτριλίου και κρυσταλλικές τροποποιήσεις αυτού. Η παρούσα εφεύρεση σχετίζεται επίσης με διαδικασίες για την παρασκευή αυτών των κρυσταλλικών τροποποιήσεων, καθώς και τη χρήση τους στη θεραπεία και /ή την πρόληψη φυσιολογικών και /ή παθοφυσιολογικών καταστάσεων, οι οποίες προκαλούνται, προέρχονται και /ή αναπαράγονται από την αναστολή, ρύθμιση και /ή τροποποίηση της μεταγωγής σημάτων των κινασών, συγκεκριμένα από την αναστολή των κινασών τυροσίνης, π.χ. παθοφυσιολογικών καταστάσεων όπως είναι ο καρκίνος.
CY20141100845T 2009-01-08 2014-10-15 Νεες πολυμορφικες μορφες του υδροχλωρικου αλατος 3-(1-{3-[5-(1-μεθυλ-πιπεριδιν-4-υλμεθοξυ)-πυριμιδιν-2-υλ]-βενζυλ}-6-οξο-1,6-διυδρο-πυριδαζιν-3-υλ)-βενζονιτριλιου και διαδικασιες για την παρασκευη του CY1115631T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09000140 2009-01-08
EP09764204.5A EP2373640B1 (en) 2009-01-08 2009-12-04 Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof

Publications (1)

Publication Number Publication Date
CY1115631T1 true CY1115631T1 (el) 2017-01-04

Family

ID=41572530

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100845T CY1115631T1 (el) 2009-01-08 2014-10-15 Νεες πολυμορφικες μορφες του υδροχλωρικου αλατος 3-(1-{3-[5-(1-μεθυλ-πιπεριδιν-4-υλμεθοξυ)-πυριμιδιν-2-υλ]-βενζυλ}-6-οξο-1,6-διυδρο-πυριδαζιν-3-υλ)-βενζονιτριλιου και διαδικασιες για την παρασκευη του

Country Status (32)

Country Link
US (3) US8710058B2 (el)
EP (1) EP2373640B1 (el)
JP (2) JP5719781B2 (el)
KR (2) KR101730791B1 (el)
CN (1) CN102272121B (el)
AR (1) AR074996A1 (el)
AU (1) AU2009336839B2 (el)
BR (1) BRPI0922642B8 (el)
CA (4) CA2749012C (el)
CL (1) CL2011001356A1 (el)
CO (1) CO6400191A2 (el)
CY (1) CY1115631T1 (el)
DK (1) DK2373640T3 (el)
EA (1) EA019342B1 (el)
EC (1) ECSP11011248A (el)
ES (1) ES2522629T3 (el)
HK (1) HK1164856A1 (el)
HR (1) HRP20140908T1 (el)
IL (1) IL213829A0 (el)
MX (3) MX350894B (el)
MY (1) MY160017A (el)
NZ (1) NZ594404A (el)
PE (2) PE20141317A1 (el)
PL (1) PL2373640T3 (el)
PT (1) PT2373640E (el)
SG (2) SG10201504735QA (el)
SI (1) SI2373640T1 (el)
SM (1) SMT201400161B (el)
TW (1) TWI475997B (el)
UA (1) UA106220C2 (el)
WO (1) WO2010078897A1 (el)
ZA (1) ZA201105782B (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8710058B2 (en) * 2009-01-08 2014-04-29 Merck Patent Gmbh Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
US20150044211A1 (en) * 2012-03-19 2015-02-12 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds
PL2914264T3 (pl) * 2012-11-02 2017-12-29 Merck Patent Gmbh Pochodna 6-okso-1,6-dihydropirydazyny do zastosowania w leczeniu raka wątrobowokomórkowego (hcc)
CA2935889C (en) * 2014-01-07 2022-08-16 Merck Patent Gmbh A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of renal cell carcinoma (rcc)
KR20170090499A (ko) 2014-12-12 2017-08-07 메르크 파텐트 게엠베하 Ｅｇｆｒ 억제제와 항암 활성을 갖는 6-옥소-1,6-디히드로-피리다진 유도체의 조합
US11179392B2 (en) 2015-04-03 2021-11-23 Impact Therapeutics, Inc. Solid pharmaceutical formulation of PARP inhibitors and use thereof
WO2016192831A1 (en) 2015-05-29 2016-12-08 Merck Patent Gmbh Compositions of anions and cations with pharmacological activity
KR20180092096A (ko) 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
US11465986B2 (en) 2018-04-26 2022-10-11 Fujian Akeylink Biotechnology Co., Ltd. Crystal form of c-MET inhibitor and salt form thereof and preparation method therefor
PT3996688T (pt) * 2019-07-10 2023-11-29 Merck Patent Gmbh Preparação farmacêutica
WO2022063869A2 (en) 2020-09-24 2022-03-31 Merck Patent Gmbh Compounds for the treatment of viral infections
KR102489160B1 (ko) 2021-05-26 2023-01-18 주식회사 이노큐어테라퓨틱스 피페리딘디온 유도체
WO2022250350A1 (ko) 2021-05-26 2022-12-01 주식회사 이노큐어테라퓨틱스 피페리딘디온 유도체
EP4346829A1 (en) 2021-06-04 2024-04-10 Merck Patent GmbH Compounds for the treatment of glioblastoma
CN114394957B (zh) * 2021-12-24 2023-05-09 武汉九州钰民医药科技有限公司 Met抑制剂盐酸特泊替尼的制备方法
KR20230155324A (ko) 2022-05-03 2023-11-10 주식회사 이노큐어테라퓨틱스 피페리딘디온 유도체
CN116768868B (zh) * 2023-08-15 2023-12-08 云南省药物研究所 一种哒嗪酮硫代衍生物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094909B2 (en) * 2001-06-11 2006-08-22 Agouron Pharmaceuticals, Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
US7169932B2 (en) * 2001-06-11 2007-01-30 Pfizer Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis
CA2536135C (en) * 2003-08-19 2012-05-22 Boehringer Ingelheim International Gmbh Multivitamin syrup for children or young adults
WO2005026114A1 (en) * 2003-09-17 2005-03-24 Pfizer Inc. Hiv protease inhibitors, compositions containing the same and their pharmaceutical uses
TW200616634A (en) * 2004-10-01 2006-06-01 Bristol Myers Squibb Co Crystalline forms and process for preparing spiro-hydantoin compounds
WO2006043145A1 (en) * 2004-10-21 2006-04-27 Pfizer Inc. Inhibitors of hepatitis c virus protease, and compositions and treatments using the same
CN101052633A (zh) * 2004-11-02 2007-10-10 辉瑞大药厂 制备吲唑化合物的方法
BRPI0518203A2 (pt) * 2004-11-02 2009-03-10 Pfizer mÉtodos para preparaÇço de compostos indazol
DE102005057924A1 (de) * 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
KR101402474B1 (ko) * 2006-04-26 2014-06-19 제넨테크, 인크. 포스포이노시티드 3-키나제 억제제 화합물 및 이를 포함하는 약학적 조성물
US7820812B2 (en) * 2006-07-25 2010-10-26 Abbott Laboratories Methods of manufacturing crystalline forms of rapamycin analogs
US7812032B2 (en) * 2006-07-25 2010-10-12 Abbott Laboratories Crystalline forms of rapamycin analogs
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
US8710058B2 (en) * 2009-01-08 2014-04-29 Merck Patent Gmbh Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof

Also Published As

Publication number Publication date
CL2011001356A1 (es) 2011-09-30
MY160017A (en) 2017-02-15
BRPI0922642B1 (pt) 2020-09-29
ZA201105782B (en) 2012-04-25
KR101730791B1 (ko) 2017-04-27
TWI475997B (zh) 2015-03-11
US8710058B2 (en) 2014-04-29
PT2373640E (pt) 2014-09-30
EP2373640A1 (en) 2011-10-12
PE20120474A1 (es) 2012-05-04
MX350894B (es) 2017-09-22
UA106220C2 (ru) 2014-08-11
CO6400191A2 (es) 2012-03-15
KR20110111472A (ko) 2011-10-11
PE20141317A1 (es) 2014-09-26
SG10201504735QA (en) 2015-07-30
JP2015038148A (ja) 2015-02-26
US20140200221A1 (en) 2014-07-17
ES2522629T3 (es) 2014-11-17
MX363848B (es) 2019-04-05
CA3014648A1 (en) 2010-07-15
CA3014648C (en) 2021-06-01
KR101829595B1 (ko) 2018-02-14
CA2749012A1 (en) 2010-07-15
PL2373640T3 (pl) 2014-12-31
WO2010078897A1 (en) 2010-07-15
EA019342B1 (ru) 2014-02-28
JP5860126B2 (ja) 2016-02-16
NZ594404A (en) 2013-04-26
JP2012514609A (ja) 2012-06-28
SG172831A1 (en) 2011-08-29
HRP20140908T1 (hr) 2014-11-07
US9289427B2 (en) 2016-03-22
TW201029655A (en) 2010-08-16
US9308205B2 (en) 2016-04-12
MX2011007322A (es) 2011-07-29
SI2373640T1 (sl) 2014-11-28
SMT201400161B (it) 2015-01-15
US20110269767A1 (en) 2011-11-03
BRPI0922642B8 (pt) 2021-05-25
DK2373640T3 (da) 2014-10-06
HK1164856A1 (en) 2012-09-28
CA2949515C (en) 2018-10-23
AU2009336839A1 (en) 2011-08-25
EP2373640B1 (en) 2014-07-30
CN102272121A (zh) 2011-12-07
AR074996A1 (es) 2011-03-02
CA3097370A1 (en) 2010-07-15
CN102272121B (zh) 2014-12-10
JP5719781B2 (ja) 2015-05-20
IL213829A0 (en) 2011-07-31
KR20170047408A (ko) 2017-05-04
CA2749012C (en) 2017-01-31
ECSP11011248A (es) 2011-10-31
US20150148351A1 (en) 2015-05-28
AU2009336839B2 (en) 2015-12-24
EA201101039A1 (ru) 2012-02-28
AU2009336839A8 (en) 2011-09-08
BRPI0922642A2 (pt) 2016-01-05
CA2949515A1 (en) 2010-07-15
MX363852B (es) 2019-04-05

Similar Documents

Publication Publication Date Title
CY1115631T1 (el) Νεες πολυμορφικες μορφες του υδροχλωρικου αλατος 3-(1-{3-[5-(1-μεθυλ-πιπεριδιν-4-υλμεθοξυ)-πυριμιδιν-2-υλ]-βενζυλ}-6-οξο-1,6-διυδρο-πυριδαζιν-3-υλ)-βενζονιτριλιου και διαδικασιες για την παρασκευη του
CY1113642T1 (el) Γεφυρωμενες δικυκλικες ετεροαρυλ υποκατεστημενες τριαζολες, χρησιμες ως αναστολεις της axl
CL2012001221A1 (es) Compuestos derivados de 4 -(1h-pirrol-1-il) pirimidin -2-ilamino y 4 -(1h-pirazol-1-il)- pirimidin-2-ilamino, inhibidores de quinasa; un compuesto isomerico; composicion farmaceutica; utiles en el tratamiento del asma, enfermedad pulmonar obstructiva cronica, colitis ulcerante, enfermedad de crohn, bronquitis, dermatitis, entre otras.
CY1117780T1 (el) Παραγωγα 1,2,4-τριαζονο-4-αμινης
HK1222124A1 (zh) 用於實體腫瘤的治療的布魯頓酪氨酸激酶的抑制劑
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
UA111933C2 (uk) Піролопіридини як інгібітори кінази
GT201200150A (es) Método para el tratamiento de trastornos proliferativos y otras condiciones patológicas mediadas por la actividad de cinasa de brc-abl,c-kit, ddr1, ddr2 o pdgf-r
IL220155B (en) History of 2, 4-(phenyl-amine-)di-converted pyrimidines for use as kinase inhibitors
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
EA201200565A1 (ru) ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
CL2011000295A1 (es) Compuestos derivados de pirimidil-amino-benzamida; inhibidores de tirosin-quinasa; y su uso en el tratamiento de la hipertension pulmonar.
MX2012004709A (es) Metodo para el tratamiento de transtornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r.
BR112014007718A2 (pt) método para preparar hidrocloreto de 1-(4-(4-(3,4-dicloro-2-fluorofenilamino)-7-metoxiquinazolin-6-iloxi)piperidin-1-il)-prop-2-en-1-ona e intermediários usados no mesmo
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
UA107336C2 (ru) Синтез и солевые формы (r)-5-((e)-2-пирролидин-3-илвинил) пиримидина
MX2011007990A (es) Intermediarios clave para la sintesis de rosuvastatina o de sales farmaceuticamente aceptables de la misma.
CY1114659T1 (el) Καινοτομες πολυμορφικες μορφες της διυδρογονοφωσφορικης 6-(1-μεθυλ-1η-πυραζολ-4- υλ)-2-{3-[5-(2-μορφολιν-4-υλ-αιθοξυ)-πυριμιδιν-2-υλ]-βενζυλ}-2η-πυριδαζιν-3-ονης και διαδικασιες παρασκευης αυτων
EA201101042A1 (ru) Производные бензотиазолона
PH12016502432A1 (en) 1h-1,8-naphthyridin-2-ones as anti proliferative compounds
CY1120792T1 (el) Συνδυασμος μεταξυ 3-[(3-{[4-(4-μορφολινυλμεθυλ)-1η-πυρρολ-2-υλ] μεθυλενο}-2-οξο-2,3-διϋδρο-1η-ινδολ-5-υλ)μεθυλ]-1,3-θειαζολιδινο-2,4-διονης και ενος αναστολεα κινασης-tyr toy egfr
TH108525A (th) รูปพหุสัณฐานชนิดใหม่ของเกลือไฮโดรคลอไรด์ของ 3-(1-{3-[5-(1-เมธิล-พิเพอริดิน-4-อิลเมธอกซิ)-พิริมิดิน-2-อิล]-เบนซิล}-6-ออกโซ-1,6-ไดไฮโดร-พิริดาซิน-3-อิล)-เบนโซไนไทรล์ และกรรมวิธีการผลิตพวกมัน
EA201101038A1 (ru) Производные пиридазинона